Draft NECTA Program
DAY 1
8-810 Introduction - Dr Anthony Joshua
810-830 “Site Australia”- Advantages of doing trials in Australia – Overview – Dr Madeline Strach /Dr Jayesh Desai
PLENARY
Session 1 Chair Dr Charlotte Lemech – Scientia Clinical Research
830-930 Dr Tobi Arkenau (including 15m discussion)
930-1030 Dr Rami Ibrahim (including 15m discussion)
1030-1045 Discussion together
1045-1115 Morning Tea
Session 2 Chair Dr Amy Prawira – Kinghorn Cancer Centre
1115-1130 Pipeline 1 - Novartis
1130-1145 Pipeline 2 - Pfizer
1145-12 Pipeline 3 - Amgen
12-1215 Pipeline - Sanofi
1215-1 Lunch
Session 3 Chair Dr James Lynam – Hunter Cancer Alliance
1-130 Dr Aaron Hansen Integrating the patient perspective into Phase 1 studies
130-2 Dr CS Pramesh Global cancer drug development - priorities and issues
2-230 Afternoon Tea
Session 4 Chair Professor Hui Gan, Olivia Newton-John Cancer Research Institute
230-3 Dr Michael Coory - The TGA view of drug approval - Evidentiary standards of 2020
3-330 Anita van der Meer - Moving Early phase trials forward in NSW
330-4 Dr Andrew Wilson - The PBS and drug reimbursement - Perspectives
4-430 Discussion
DAY 2
Session 1 Chair Dr Mun Hui - Lifehouse
8-845 Dr Andrew Mortlock - AstraZeneca
845-930 Dr Jean-Francois Martini - Pfizer
930-950 Dr Derek Richard - Advances in Drug Development - The Brisbane experience
950-1015 Discussion – The Interplay between Industry and Academia in Pharma
including Dr Steven Ackland, Dr Ben Markman
1015-1045 Morning Tea
Session 2 Chair – Dr Michael Millward, Charles Gardiner/ Linear Perth
1045-1100 Pipeline 1- Cstone
1100-1115 Pipeline 2- MSD Australia
1115-1135 Pipeline 3 – BMS
1135-1155 Pipieline 4- Boehringer Ingleheim
1155-1215 Pipeline 5 - Bayer
1220-120 Lunch
Session 3 Chair – Dr Adnan Nagrial, Westmead
120-150 Dr Justin Coombs - Developing Car-T in Australia
150-235 Dr John Rasko - CAR-T cells at RPA
235-310 Dr Simon Harrison - Peter Mac
310-340 Discussion– Are we ready for Car-T in solid tumours?
DAY 1
8-810 Introduction - Dr Anthony Joshua
810-830 “Site Australia”- Advantages of doing trials in Australia – Overview – Dr Madeline Strach /Dr Jayesh Desai
PLENARY
Session 1 Chair Dr Charlotte Lemech – Scientia Clinical Research
830-930 Dr Tobi Arkenau (including 15m discussion)
930-1030 Dr Rami Ibrahim (including 15m discussion)
1030-1045 Discussion together
1045-1115 Morning Tea
Session 2 Chair Dr Amy Prawira – Kinghorn Cancer Centre
1115-1130 Pipeline 1 - Novartis
1130-1145 Pipeline 2 - Pfizer
1145-12 Pipeline 3 - Amgen
12-1215 Pipeline - Sanofi
1215-1 Lunch
Session 3 Chair Dr James Lynam – Hunter Cancer Alliance
1-130 Dr Aaron Hansen Integrating the patient perspective into Phase 1 studies
130-2 Dr CS Pramesh Global cancer drug development - priorities and issues
2-230 Afternoon Tea
Session 4 Chair Professor Hui Gan, Olivia Newton-John Cancer Research Institute
230-3 Dr Michael Coory - The TGA view of drug approval - Evidentiary standards of 2020
3-330 Anita van der Meer - Moving Early phase trials forward in NSW
330-4 Dr Andrew Wilson - The PBS and drug reimbursement - Perspectives
4-430 Discussion
DAY 2
Session 1 Chair Dr Mun Hui - Lifehouse
8-845 Dr Andrew Mortlock - AstraZeneca
845-930 Dr Jean-Francois Martini - Pfizer
930-950 Dr Derek Richard - Advances in Drug Development - The Brisbane experience
950-1015 Discussion – The Interplay between Industry and Academia in Pharma
including Dr Steven Ackland, Dr Ben Markman
1015-1045 Morning Tea
Session 2 Chair – Dr Michael Millward, Charles Gardiner/ Linear Perth
1045-1100 Pipeline 1- Cstone
1100-1115 Pipeline 2- MSD Australia
1115-1135 Pipeline 3 – BMS
1135-1155 Pipieline 4- Boehringer Ingleheim
1155-1215 Pipeline 5 - Bayer
1220-120 Lunch
Session 3 Chair – Dr Adnan Nagrial, Westmead
120-150 Dr Justin Coombs - Developing Car-T in Australia
150-235 Dr John Rasko - CAR-T cells at RPA
235-310 Dr Simon Harrison - Peter Mac
310-340 Discussion– Are we ready for Car-T in solid tumours?